Financial Performance - The company's operating revenue for 2024 was ¥795,597,751.21, a decrease of 11.17% compared to ¥895,592,665.42 in 2023[17]. - The net profit attributable to shareholders was -¥87,804,417.25, compared to -¥8,927,328.47 in the previous year[17]. - Total revenue for 2024 was ¥795,597,751.21, a decrease of 11.2% from ¥895,592,665.42 in 2023[18]. - Main business revenue after deductions was ¥782,537,037.69, down from ¥874,248,180.09 in 2023, indicating a decline of 10.5%[18]. - In Q1 2024, the net profit attributable to shareholders was -¥4,575,299.38, while in Q2 it was ¥5,903,467.39, followed by a significant loss of -¥27,744,860.11 in Q3 and -¥61,387,725.15 in Q4[20]. - The company reported a total of ¥31,065,285.63 in non-recurring gains and losses for 2024, compared to ¥51,006,000.74 in 2023[25]. - The company’s revenue from products accounting for over 10% of total revenue includes Nano Carbon Suspension Injection, which is used for lymph node tracing in gastric cancer[45]. - The company reported a total revenue of 120.4 million in June 2023, an increase from 117.9 million in June 2020, reflecting a growth of approximately 2.12%[110]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% year-over-year growth[124]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in Q4 2023[128]. Cash Flow and Investments - The net cash flow from operating activities increased by 126.94% to ¥185,030,045.99 from ¥81,531,393.12 in 2023[17]. - The cash flow from operating activities for 2024 was ¥79,222,721.89, an increase from ¥43,587,440.19 in 2023[21]. - The company achieved a net increase in cash and cash equivalents of CNY 357,099,055.17 in 2024, compared to a decrease of CNY 126,252,393.25 in 2023[65]. - The company reported a significant increase in investment activity cash inflow by 30.35%, from CNY 68,167,256.64 in 2023 to CNY 88,855,739.96 in 2024[65]. - The company reported a net loss from investment activities of CNY 18,309,523.44, an improvement from a loss of CNY 127,108,257.01 in 2023[65]. - The company’s investment income was reported at -CNY 18,877,654.65, accounting for 24.99% of total profit, indicating challenges in non-core business areas[68]. Research and Development - The company plans to increase R&D investment and expand into pharmaceutical distribution and medical devices to improve overall business scale and profitability[29]. - The total R&D investment for 2024 was CNY 94,990,480.97, accounting for 11.94% of operating revenue, a decrease from 12.67% in 2023[63]. - The number of R&D personnel decreased by 8.64% from 81 in 2023 to 74 in 2024, with the proportion of R&D personnel in the company dropping from 10.13% to 7.26%[63]. - The company has established a multi-level research and innovation system, focusing on short, medium, and long-term core product development[35]. - The company is committed to independent innovation and has increased its R&D investment to accelerate the development of strategic products in niche markets[43]. - The company is actively pursuing new product development, with several drugs currently in the application or research stages, including Azithromycin Granules and Triptorelin Acetate[46]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy[128]. Market and Product Development - The company has focused on innovative drug development, with ongoing projects in mRNA vaccines and nanocarbon products, enhancing its competitive edge in the market[29]. - The company has received approvals for 10 new products, enhancing its product line and market competitiveness[29]. - The company aims to enhance its competitive position by optimizing its product structure and improving innovation capabilities in response to the pressures of centralized procurement[32]. - The company is actively pursuing strategic collaborations and investments to identify potential products and technologies that align with its development needs[35]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[124]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[128]. Regulatory and Compliance - The company faces risks related to industry policies, drug price reductions, product quality, and technology development[5]. - The company reported that its recent audit indicated uncertainty regarding its ability to continue as a going concern[17]. - The company has strengthened its governance and compliance with regulatory requirements, enhancing its capital market image[48]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and accountability[101]. - The company is committed to ensuring compliance with legal rulings and managing its financial obligations accordingly[182]. - The company has committed to avoiding competition with its controlling entities and has adhered to this commitment throughout the reporting period[168]. Environmental and Social Responsibility - The company has implemented strict environmental standards for waste management, but faces potential risks from new regulations and equipment failures[95]. - Laimei Pharmaceutical has a wastewater treatment system with a capacity of 400m³/d, which has been operating normally throughout 2024[157]. - Laimei Longyu operates a wastewater treatment system with a capacity of 500m³/d, also functioning normally in 2024[158]. - Laimei Pharmaceutical's wastewater treatment facility has achieved compliance with all relevant environmental regulations and standards throughout 2024[157]. - The company has established emergency response plans for environmental incidents, which have been filed with local ecological environment authorities[161]. Corporate Governance - The company has a dedicated investor relations team to enhance communication and maintain a positive image in the capital market[104]. - The company has maintained independence from its controlling shareholders in terms of assets, personnel, and financial operations[105]. - The company has a complete human resources management system, ensuring compliance with relevant laws and regulations in the appointment of directors and senior management[106]. - The company has established and updated internal control systems in compliance with relevant laws and regulations, enhancing risk management[146]. - The company has not encountered significant discrepancies between its governance practices and regulatory requirements[104]. Legal Matters - The company is involved in ongoing litigation with Chengdu Jinxing, with a first-instance judgment ordering the defendant to return 8.409 million yuan[182]. - The company has filed a lawsuit seeking the return of legal fees amounting to 71,738 yuan from Chengdu Jinxing[182]. - The company is currently awaiting the outcome of a second-instance trial regarding the aforementioned case[182]. - The company’s financial performance is impacted by ongoing legal disputes, which may affect future profitability[182].

关于重庆莱美药业股份有限公司 2024 年度 非经营性资金占用及其他关联资金往来情况 专项审核说明 康华专审 B（2025）A15 号 重庆康华会计师事务所 （特殊普通合伙） 二〇二五年三月 重 庆 康 华 会 计 师 事 务 所 CHONGQING KANGHUA CPAs 1 关于重庆莱美药业股份有限公司 2024 年度非经营性资金占用及其他关联资金 往来情况专项审核说明 康华专审 B（2025）A15 号 3.重庆康华会计师事务所（特殊普通合伙）执业证书复印件 4.注册会计师执业证书复印件 我们接受委托，依据中国注册会计师审计准则审计了重庆莱美药业股份有限公司 （以下简称"莱美药业"）2024 年 12 月 31 日的资产负债表、2024 年度的利润表、股东 权益变动表和现金流量表，并于 2025 年 3 月 20 日签发了康华表审（2025）A66 号标准 无保留意见的审计报告。 按照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》(证 监会公告[2022]26 号)，以及深圳证券交易所相关披露的要求，莱美药业编制了后附的 2024 年度非经营性资金占用及其他关联资金往来情况汇总 ...

关于重庆莱美药业股份有限公司 2024 年度 营业收入扣除事项的专项核查报告 专项核查报告 康华专审 B（2025）A16 号 重庆康华会计师事务所 （特殊普通合伙） 二〇二五年三月 三、 专项核查意见 重 庆 康 华 会 计 师 事 务 所 Chongqing Kanghua CPAs 1 关于重庆莱美药业股份有限公司 2024 年度营业收入扣除事项的专项核查报告 康华专审 B（2025）A16 号 重庆莱美药业股份有限公司： 我们接受委托，依据中国注册会计师审计准则审计了重庆莱美药业股份有限公司（以 下简称"莱美药业"）2024 年 12 月 31 日的资产负债表、2024 年度的利润表、股东权益变 动表和现金流量表，并于 2025 年 3 月 20 日签发了康华表审（2025）A66 号标准无保留意 见的审计报告。在此基础上，我们检查了后附的莱美药业管理层编制的《2024 年度营业收 入扣除情况表》(以下简称"营业收入扣除情况表")。 一、 管理层的责任 莱美药业管理层的责任是提供真实、合法、完整的相关资料，按照《深圳证券交易所 创业板股票上市规则》及《深圳证券交易所创业板上市公司自律监管指南第 1 号 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-007 重庆莱美药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 近日，重庆莱美药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的注射用尼可地尔 2mg 和 12mg 两种规格的《药品注册证书》， 现将有关事宜公告如下： | 药品名称 | 药品通用名称：注射用尼可地尔 | | | --- | --- | --- | | | 英文名/拉丁名：Nicorandil for Injection | | | 主要成份 | 尼可地尔 | | | 剂型 | 注射剂 | | | 规格 | 2mg | 12mg | | 证书编号 | 2025S00571 | 2025S00572 | | 药品注册标准编号 | YBH02962025 | YBH02962025 | | 包装规格 | 10 瓶/盒 | 10 瓶/盒 | | 申请事项 | 药品注册（境内生产） | 药品注册（境内生产） | | 注册分类 | 化学药品 3 类 | 化学药品 3 类 | | 药品 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-006 重庆莱美药业股份有限公司 关于参与投资广东东纳协同产业投资合伙企业（有限 合伙）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、重庆莱美药业股份有限公司（以下简称"公司""莱美药业"）作为有 限合伙人以自有资金 4,000 万元人民币参与投资广东东纳协同产业投资合伙企业 （有限合伙）（以下简称"合伙企业""东纳协同"），本次认缴完成后公司将 持有东纳协同 43.9560%的合伙份额；东纳协同资金仅定向用于认购/申购广东东 纳私募基金管理有限公司所管理的广东东纳医健创业投资合伙企业（有限合伙） （以下简称"东纳医疗基金"）合伙份额。 2、根据《公司章程》等规定，本次交易已提交公司董事会和监事会审议通 过，无需提交公司股东大会审议；本次交易不构成关联交易，亦不构成《上市公 司重大资产重组管理办法》规定的重大资产重组。 3、公司将根据本次投资的后续进展情况，按照相关法律法规的规定和《公 司章程》的要求及时履行相应的信息披露义务，敬请广大投资者注意投资风险。 一、对外投资概 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-005 重庆莱美药业股份有限公司 第五届监事会第三十六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1、公司第五届监事会第三十六次会议决议。 特此公告。 重庆莱美药业股份有限公司 监事会 一、审议通过《关于参与投资广东东纳协同产业投资合伙企业（有限合伙） 的议案》 为进一步优化投资结构，提升投资价值，加速布局医药健康产业链中高壁垒、 高成长性战略环节，同意公司以自有资金 4,000 万元认购广东东纳协同产业投资 合伙企业（有限合伙）的合伙份额，并成为该合伙企业的有限合伙人，本次投资 完成后，公司将持有该合伙企业 43.9560%的合伙份额。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于参与投资广东东纳协同产业投资合伙企业（有限合伙）的公告》。 表决结果：3 票同意、0 票反对、0 票弃权。 二、备查文件 重庆莱美药业股份有限公司（以下简称"公司"）监事会于 2025 年 2 月 27 日以通讯方式向全体监事发出会议通知。本次会 ...

重庆莱美药业股份有限公司（以下简称"公司"）董事会办公室于 2025 年 2 月 27 日以通讯方式向全体董事发出会议通知。本次会议于 2025 年 3 月 4 日以通讯表决方式召开。本次会议应出席董事 9 名，实际出席董事 9 名。本 次会议的召集、召开符合《中华人民共和国公司法》《公司章程》及有关法律 法规的规定。本次会议由公司董事长梁建生先生主持。经出席会议董事审议 和书面表决，形成了以下决议： 证券代码：300006 证券简称：莱美药业 公告编号：2025-004 重庆莱美药业股份有限公司 第五届董事会第四十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 二、备查文件 1、第五届董事会第四十二次会议决议。 一、审议通过了《关于参与投资广东东纳协同产业投资合伙企业（有限合伙） 的议案》 为进一步优化投资结构，提升投资价值，加速布局医药健康产业链中高壁垒、 高成长性战略环节，同意公司以自有资金 4,000 万元认购广东东纳协同产业投资 合伙企业（有限合伙）的合伙份额，并成为该合伙企业的有限合伙人，本次投资 完成后，公司将持有该合伙企业 4 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-003 重庆莱美药业股份有限公司 关于持股 5%以上股东所持部分股份 被动减持的预披露公告 公司持股 5%以上股东邱宇保证向本公司提供的信息内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、重庆莱美药业股份有限公司（以下简称"公司"）持股 5%以上股东邱宇 因与国海证券股份有限公司（以下简称"国海证券"）开展质押式证券回购业务 相关债务逾期，国海证券拟依据广西壮族自治区南宁市青秀区人民法院出具的 《协助执行通知书》，将通过集中竞价方式继续处置邱宇持有的 67.48 万股公司 股份（占公司总股本的 0.06%）。本次减持计划自本公告披露之日起 15 个交易 日后的 3 个月内进行，且任意连续 90 个自然日内通过集中竞价交易减持股份的 总数不超过公司股份总数的 1%。 1、股东名称：邱宇 2、减持原因：因邱宇与国海证券质押式证券回购业务相关债务逾期，国海 证券将通过集中竞价方式继续减持邱宇持有的 67.48 万股公司股份（占公司总股 本的 0.06%）。 ...

重庆莱美药业股份有限公司 关于持股 5%以上股东被动减持期限届满的公告 证券代码：300006 证券简称：莱美药业 公告编号：2025-002 持股 5%以上股东邱宇先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重庆莱美药业股份有限公司（以下简称"公司"）公司于2024年10月15日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于持股5%以上股东所持部分股份 被动减持的预披露公告》（公告编号：2024-036），公司持股5%以上股东邱宇因 与国海证券股份有限公司（以下简称"国海证券"）开展质押式证券回购业务相 关债务逾期，国海证券拟通过集中竞价方式继续处置邱宇持有的755.40万股公司 股份，上述减持计划自披露之日起15个交易日（2024年11月5日）后的3个月内进 行，且任意连续90个自然日内通过集中竞价交易减持股份的总数不超过公司股份 总数的1%。 公司于近日收到股东邱宇出具的《关于股份被动减持计划期限届满的告知 函》，获悉持股5%以上股东邱宇本次减持计划期限已届满。根据《上市公司 ...

Financial Performance - The company expects a net loss of between 83 million and 98 million RMB for the fiscal year 2024, compared to a loss of 8.93 million RMB in the same period last year[2] - The expected net loss after deducting non-recurring gains and losses is between 114.95 million and 129.95 million RMB, compared to a loss of 59.93 million RMB in the previous year[2] - The decline in sales volume and prices of certain products has led to a decrease in operating revenue[4] - Non-recurring gains and losses are expected to impact net profit by approximately 31.95 million RMB[4] R&D and Investment - The company has increased R&D investment, which has impacted operating profit[4] - The company anticipates recognizing an investment loss of about 20.5 million RMB from certain joint ventures due to increased R&D expenses and fair value changes[4] Asset Impairment - An impairment of intangible assets is estimated at approximately 26 million RMB[4] Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2024 annual report[5]